Biosergen AB (SE:BIOSGN)
:BIOSGN
Top Page
Biosergen AB
(BIOSGN)
Select Model
Select Model
Rating:42Neutral
Price Target:
kr42.00
▼(-1.41% Downside)
Action:UpgradedDate:12/30/25
The score is primarily weighed down by weak financial performance (pre-revenue, recurring losses, and ongoing cash burn) and bearish technical signals (below major moving averages with negative MACD). A debt-free balance sheet with improved equity provides some support, but valuation remains challenged by negative earnings and no dividend data.
Positive Factors
Targeted antifungal pipeline
Biosergen’s focus on BSG005 for invasive fungal infections addresses a structural unmet need in hospital and critical‑care settings where resistance and toxicity limit options. A successful clinical/regulatory outcome would create a durable franchise in a niche with high clinical importance and limited competition.
Negative Factors
Pre‑revenue with ongoing losses
The absence of recurring revenue and persistent sizeable net losses mean the company must continually access capital to fund operations. This structural dependence on external financing increases dilution risk and leaves long‑term viability contingent on successful clinical or partnering outcomes rather than operating cash generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Targeted antifungal pipeline
Biosergen’s focus on BSG005 for invasive fungal infections addresses a structural unmet need in hospital and critical‑care settings where resistance and toxicity limit options. A successful clinical/regulatory outcome would create a durable franchise in a niche with high clinical importance and limited competition.
Read all positive factors
Biosergen AB (BIOSGN) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr85.01M
Dividend YieldN/A
Average Volume (3M)126.26K
Price to Earnings (P/E)―
Beta (1Y)-0.46
Revenue GrowthN/A
EPS Growth49.09%
CountrySE
Employees2
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,348,232
10 Day Avg. Volume207,862
30 Day Avg. Volume126,261
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)2.64
Price to Sales (P/S)0.00
P/FCF Ratio-7.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Biosergen AB Business Overview & Revenue Model
Company Description
Biosergen AB, a biopharmaceutical company, engages in the development of antifungal products. It is developing BSG005, an antifungal drug candidate for the treatment of life threatening invasive fungal diseases. The company was founded in 2004 and...
How the Company Makes Money
Biosergen AB generates revenue primarily through the development and commercialization of its antifungal drug candidates. The company engages in various stages of clinical trials to bring its products to market, potentially partnering with larger ...
Biosergen AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
52
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 8.57M | 4.43M |
| Gross Profit | 0.00 | 0.00 | -456.00K | -280.00K | -213.60K | -6.10M |
| EBITDA | -24.15M | -19.20M | 228.00K | -39.99M | -34.32M | -6.72M |
| Net Income | -24.27M | -19.20M | -27.04M | -34.05M | -34.32M | -6.72M |
Balance Sheet | ||||||
| Total Assets | 37.93M | 52.85M | 7.20M | 33.79M | 29.49M | 4.80M |
| Cash, Cash Equivalents and Short-Term Investments | 33.27M | 50.61M | 1.88M | 29.34M | 21.66M | 589.00K |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 5.35M | 3.71M | 5.08M | 11.00M | 9.25M | 15.72M |
| Stockholders Equity | 32.58M | 48.21M | 2.12M | 22.79M | 20.23M | -10.92M |
Cash Flow | ||||||
| Free Cash Flow | -14.15M | -16.63M | -32.60M | -29.44M | -37.75M | -4.58M |
| Operating Cash Flow | -14.15M | -16.63M | -32.60M | -29.44M | -37.75M | -4.58M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 41.09M | 65.36M | 5.14M | 37.12M | 58.83M | 0.00 |
Biosergen AB Technical Analysis
Negative
42.60
Price Trends
40.11
Negative
42.54
Negative
46.44
Negative
Market Momentum
-1.04
Negative
38.05
Neutral
47.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BIOSGN, the sentiment is Negative. The current price of 42.6 is above the 20-day moving average (MA) of 37.56, above the 50-day MA of 40.11, and below the 200-day MA of 46.44, indicating a bearish trend. The MACD of -1.04 indicates Negative momentum. The RSI at 38.05 is Neutral, neither overbought nor oversold. The STOCH value of 47.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:BIOSGN.
Biosergen AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | kr67.48M | -1.64 | -106.95% | ― | -48.15% | 51.95% | |
44 Neutral | kr141.02M | -1.48 | -52.45% | ― | 2.56% | 52.76% | |
43 Neutral | kr90.79M | -3.17 | -21.31% | ― | -67.00% | 13.62% | |
42 Neutral | kr85.01M | -1.86 | -120.13% | ― | ― | 49.09% | |
42 Neutral | kr38.43M | -1.34 | -294.38% | ― | 186.74% | 73.17% | |
41 Neutral | kr3.51M | -3.06 | -213.85% | ― | ― | ― |
* Healthcare Sector Average
SE:BIOSGN
Biosergen AB
36.20
3.50
10.70%
SE:ALZ
Alzinova AB
0.59
-2.01
-77.38%
SE:NICA
Nanologica AB
0.35
-1.05
-74.95%
SE:LPGO
Lipigon Pharmaceuticals AB
0.01
-0.09
-88.89%
SE:NXTCL
NextCell Pharma AB
1.27
-1.61
-56.04%
SE:SPAGO
Spago Nanomedical AB
0.10
-0.05
-34.19%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.